Long-lasting remission of severe Behçet's disease after the end of infliximab therapy

Journal of Rheumatology

Volumn 36, Issue 4, 2009, Pages 855-

  Olivieri, Ignazio ^a   Padula, Angela ^b   Leccese, Pietro ^b   D'Angelo, Salvatore ^b   Giasi, Vincenzo ^b  

^a SAN CARLO HOSPITAL   (Italy)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; AZATHIOPRINE; B51 ANTIGEN; CYCLOSPORIN; INFLIXIMAB; PREDNISONE; UNCLASSIFIED DRUG; ANTIINFLAMMATORY AGENT; MONOCLONAL ANTIBODY;

ADULT; APHTHOUS STOMATITIS; BEHCET DISEASE; CASE REPORT; CREATININE BLOOD LEVEL; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; ERYTHEMA NODOSUM; HLA TYPING; HUMAN; LETTER; LOW DRUG DOSE; MALE; PRIORITY JOURNAL; PUSTULOSIS; REMISSION; RETINITIS; SIDE EFFECT; TREATMENT OUTCOME; UVEITIS; NOTE; PATHOLOGY; PATHOPHYSIOLOGY;

ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; BEHCET SYNDROME; HUMANS; MALE; REMISSION INDUCTION; YOUNG ADULT;

EID: 66149088809     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: 10.3899/jrheum.081063     Document Type: Letter

References (3)

1. Olivieri I, Latanza L, Siringo S, Peruz G, Di Iorio V. Successful treatment of severe Behçet's disease with infliximab in an Italian Olympic athlete. J Rheumatol 2008;35:930-2.
2. Kural-Seyahi E, Fresko I, Seyahi N, et al. The long-term mortality and morbidity of Behçet's syndrome: a 2-decade outcome survey of 387 patients followed at a dedicated center. Medicine Baltimore 2003;82:60-76.
3. Tugal-Tutkun I, Onal S, Altan-Yaycioglu R, Huseyin Altunbas H, Urgancioglu M. Uveitis in Behçet's disease: an analysis of 880 patients. Am J Ophthalmol 2004;138:373-80.